Did your doctor pass this test of competency? Does s/he know about this and have plans to followup when complete?
A Double-Blind, Controlled Ph 2b Study of the Safety and Efficacy of Modified Stem Cells in Patients with Chronic Motor Deficit from Ischemic Stroke
Disease Area:
Investigator:
Institution:
CIRM Grant:
Award Value:
$19,998,580
Trial Sponsor:
Trial Stage:
Phase 2
Trial Status:
Active, not recruiting
Targeted Enrollment:
156
ClinicalTrials.gov ID:
Details:
Stroke is a major
cause of long-term disability and there are no proven medical treatments
for chronic stroke. SanBio is carrying out a Phase 2 clinical trial
using mesenchymal stem cells (MSCs) to help people suffering from
chronic disability following a stroke. The MSCs are isolated from the
bone marrow of healthy adult donors, and then modified to enhance their
ability to promote recovery from injury by triggering the brain’s
natural regenerative ability. Patients with stroke can suffer from loss
of mobility in certain parts of their body and the hope is that this
therapy will rescue some of these problems.
Design:
Double-blind randomized controlled study.
Goal:
Safety and efficacy compared to sham surgery - improvement in motor activity on stroke affected side. Actively recruiting.
Updates:
Actively recruiting.
News about this clinical trial:
No comments:
Post a Comment